Cancer Treatment Options & Cost in China
For international patients considering treatment in China: before making any travel decision, first understand the logic of guideline-based treatment plans — chemotherapy, precision radiation therapy, immunotherapy and targeted therapy — then match your cancer type to the right specialty pathway, see through the real structure of medical costs, and choose only national top-tier public Class-A tertiary treatment teams.
Statutory Medical Review Consensus Statement
All treatment plans, drug indications and surgical decisions are strictly based on MDT multidisciplinary consultation at a Chinese Class-A tertiary hospital, re-review of the physical pathology slides and verification of original imaging.
Chemotherapy · Radiation · Immunotherapy & Targeted Therapy: Scientifically Defining the Technical Boundaries
Cancer treatment has no single "miracle" method. Modern public Class-A tertiary hospitals practice evidence-based medicine, combining molecular biological features and TNM staging into a multidimensional treatment matrix.
Chemotherapy
Cornerstone of Systemic TreatmentCytotoxic Drugs / Neoadjuvant Downstaging / Adjuvant Consolidation
Clinical decision criteria: strictly based on the primary lesion's histologic grade, Ki-67 proliferation index and organ tolerance assessment. It is never about "newer is better" — it is about standardized cycle design and correct regimen sequencing.
Radiation Therapy & Particle Therapy
High-Precision Local Tumor ControlIMRT / SBRT / Proton & Heavy-Ion Therapy (Proton/Carbon Ion)
Understanding the technology ladder: conventional intensity-modulated radiation therapy (IMRT) and stereotactic body radiation therapy (SBRT) suit the local treatment of most solid tumors, while proton & heavy-ion therapy offers the physical dosimetric advantage of the "Bragg Peak."
Immunotherapy & Targeted Therapy
Molecular Targeting · Cellular ImmunotherapyNGS Mutation Targets / PD-(L)1 / CAR-T Cell Infusion
Prerequisite before prescribing: targeted therapy must first confirm a driver mutation through large-panel next-generation sequencing (NGS) — such as EGFR, ALK, HER2, ROS1, KRAS G12C, RET or MET. Blindly trying drugs with no confirmed target does harm without benefit.
Clinical principle before you travel: International patients coming to China do not need to "pick a technology" themselves or blindly chase expensive equipment. Once you provide complete histopathology, genetic reports and original DICOM imaging, the MDT multidisciplinary consultation at a public Class-A tertiary oncology center will directly produce the sequenced combined plan that best fits your expected survival benefit.
Precision Pathways & Verification Checklists for Common Solid Tumors
Clearly organized intake prevents patients from being shuttled between departments of a general hospital. Review below the core documents each cancer expert team needs for its initial assessment.
Breast Cancer Precision Pathway
Breast Cancer Molecular Subtyping
ER and PR expression rates, HER2 amplification status by immunohistochemistry/FISH and the Ki-67 proliferation index must be confirmed; where necessary, BRCA1/2 germline mutations and sentinel lymph node status are verified.
- Original pathology report from the biopsy, with the full immunohistochemistry panel
- Native DICOM files of breast and axillary ultrasound, mammography and MRI
- Whole-body bone scan (ECT) and contrast-enhanced chest and abdomen CT reports
- Complete medication history of prior chemotherapy, endocrine therapy and anti-HER2 targeted therapy
Prostate Cancer Specialty Pathway
Prostate Cancer & PSMA Diagnostics
Biopsy Gleason score and Grade Group, the serial PSA/fPSA trend curve, the presence of extracapsular extension and the burden level of distant bone metastases.
- Pathology report from systematic prostate biopsy
- Raw multiparametric MRI (mpMRI) DICOM data of the pelvis
- 68Ga-PSMA PET-CT report and images, if available
- Records of resistance to endocrine androgen deprivation therapy (ADT)
Pathways for More Common Malignancies
Specialized Multidisciplinary Tracks
Covers novel drugs for rare targets in non-small cell lung cancer (NSCLC), thoracoscopic minimally invasive curative surgery and radiation therapy for brain metastases.
Hyperthermic intraperitoneal chemotherapy (HIPEC) for gastric cancer, conversion surgery for colorectal liver metastases and complex hepatobiliary-pancreatic tumor resections.
Maintenance therapy for cervical and ovarian cancer, plus TCM-supportive recovery management during the myelosuppression phase.
Two Transparent Accounts: Platform Service Fee vs. Public Hospital Medical Fees, Fully Separated
Say goodbye to the information gap of traditional overseas medical agencies and hidden drug markups. Account separation and official invoicing apply throughout the entire process.
Fixed Platform Coordination Service Fee
Charged once with zero hidden markup. It funds rigorous initial medical review of your overseas records before the trip to China and direct routing to the best-matched department director at a public Class-A tertiary hospital.
Medical Fees Charged by National Public Hospitals
All outpatient, inpatient, examination, laboratory, consumable and drug fees are paid directly by the patient or family members at the hospital's official window or corporate bank account. The platform strictly prohibits any form of collection or on-behalf payment.
⚠️ Serious risk warning and industry red line: Any agency or agent claiming an "all-inclusive flat package" or asking you to "prepay for a guaranteed cure or guaranteed effectiveness" is engaging in false advertising and unlawful medical claims. China's national public Class-A tertiary hospitals issue official invoices strictly according to the actual medical services rendered and the pricing catalog of the National Health Commission. Never transfer money to any third-party personal account.
Five Core Standards for International Patients Choosing a Cancer Hospital in China
Separating the wheat from the chaff: look beyond a hospital's overall reputation to its subspecialty tiers, the real depth of multidisciplinary MDT collaboration and its closed-loop post-discharge follow-up.
Fully Verifiable Qualifications
Must be a university hospital directly under the National Health Commission or the Ministry of Education, or a high-level provincial public Class-A tertiary oncology center — with lawful international patient reception credentials and foreign-settlement invoices.
Precise Specialty & Subspecialty Matching
Do not blindly follow "large general hospitals." Care must be organized into cancer-type subspecialty disease groups — such as thoracic medical oncology, minimally invasive breast surgery or GI tumor biotherapy units — whose lead experts operate or manage an internationally leading annual volume of comparable cases.
Real, Functional MDT Mechanisms
The hospital must run a substantively operational multidisciplinary team (MDT) mechanism — never a nominal meeting. Experts from medical oncology, radiation oncology, surgery, pathology and radiology discuss the case together at one table and issue a single authoritative consensus document.
Clear Cost Range Before Treatment
Can the hospital, before admitting you, use its historical clinical pathways and single-disease quality-control data to give a reference cost range and an out-of-pocket forecast? This prevents patients from being forced to stop mid-treatment because their budget ran out.
International Channel & Cross-Border Follow-Up Loop
Beyond archiving international patients' records and writing English discharge summaries, the hospital should maintain a 6-12 month post-discharge remote follow-up coordination channel and hand over smoothly to your home-country treating physicians.
Verified Collaborative Network
MedTravel China connects directly to national medical centers in Beijing, Shanghai and Guangzhou — with fast-track cooperation channels at Sun Yat-sen University Cancer Center (SYSUCC), Cancer Hospital, Chinese Academy of Medical Sciences, Fudan University Shanghai Cancer Center and others.
FAQ: International Cancer Patients Seeking Treatment in China
Answers to the core concerns of cross-border patients and their families — process timelines, indications and budget planning.
01 Coming to China as an international patient: should I choose a hospital first, or complete the medical record pre-review first? expand_more
02 Besides the 300 USD platform coordination fee, how much medical budget should I normally prepare? expand_more
03 For breast and prostate cancer patients, which core documents should be prepared in advance? expand_more
- Pathology and molecular data: original pathology of the tissue biopsy or resection specimen with the complete immunohistochemistry report (e.g., ER/PR/HER2/Ki-67 for breast cancer, Gleason score for prostate cancer);
- Original medical imaging: complete DICOM folders copied to disc by your local hospital within the past 1 - 2 months (not photos of films taken with a phone);
- Blood markers and medication history: the PSA fluctuation curve of the past six months, tumor markers (CEA/CA153/CA125), and detailed records of chemotherapy, endocrine therapy and radiation therapy.
04 Can everyone receive proton & heavy-ion therapy or CAR-T? How is eligibility confirmed? expand_more
05 From submitting my medical records to arriving in China for admission, how long does the whole process usually take? expand_more
- Working days 1 - 2: your complete records and DICOM imaging are received, and medical coordinators finish the standardized bilingual medical record summary translation;
- Working days 3 - 5: your case is submitted to the oncology expert team of a public Class-A tertiary hospital in China, which issues a written intention plan and an admission estimate;
- Days 7 - 14: we assist you in applying for a cross-border medical treatment visa at the Chinese embassy or consulate with the hospital's official medical invitation letter, and arrange bed reservation plus expedited airport pickup and accompanied visits in China.
Clear about your treatment options and cost boundaries?
Start with a rigorous expert pre-review of your medical records.
Simply upload your existing diagnostic reports, pathology results and original DICOM imaging. The MedTravel China medical team will organize your case within 24-48 hours and present it directly for review by a leading Class-A tertiary oncology director in China.
info Medical information on this site is for general reference only and does not constitute medical advice, diagnosis, or treatment recommendations. Actual care decisions rest with the licensed physicians of the hospital.